Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
NCT Number: NCT03218761
DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.
This study is active but is not currently recruiting participants.
13 year–80 year
All sexes
Observational
Nashville, Tennessee, 37232, United States
Work from The Baker Institute in Melbourne, Australia has shown that there can be significant epigenetic modification of the Norepinephrine Transporter (NET). DNA Acetylation can be responsible for significant down-regulation of transcription. NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses.Very low levels of NET can produce a hyperadrenergic phenotype and can "cause" Postural Tachycardia Syndrome (POTS). The Baker Institute researchers have started using quantified NET mRNA levels from a peripheral blood sample to assess NET availability. This is a huge advance due to its simplicity, in contrast to a prior method which involved a vein biopsy to look at the level of protein expression.
In this protocol, the investigators seek to assess whether these NET messenger RNA (mRNA) levels correlate with NET function. When NET transports NE back into presynaptic neurons, a high percentage gets converted to a metabolite (DHPG) and then released into the blood stream. Therefore, the ratio of DHPG:NE ratio is decreased with reduced NET activity. The investigators will assess this DHPG:NE ratio in POTS patients and control subjects from both plasma and urine samples.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
o These drugs pharmacologically block NET activity
o Many tricyclic antidepressants pharmacologically block NET activity
quantification of mRNA to the Norepinephrine Transporter (NET)
plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
Time frame: 1 day
NET mRNA above and below median supine plasma DHPG:NE
Time frame: 1 day
NET mRNA above and below median standing plasma DHPG:NE
Time frame: 1 day
NET mRNA above and below median urine DHPG:NE
Vanderbilt University Medical Center
Other
Validation of Norepinephrine Transporter (NET) mRNA as a Measure of Functional NET Expression in Postural Tachycardia Syndrome (POTS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03124355
Autonomic Nervous System Diseases, Nervous System Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT05043051
Autonomic Nervous System Diseases, Nervous System Diseases
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT04140721
Autonomic Nervous System Diseases, Nervous System Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT04050410
Autonomic Nervous System Diseases, Nervous System Diseases
Nashville, Tennessee, United States
View Trial Details